Last updated: February 21, 2026
What is the current status of metharbital in the pharmaceutical market?
Metharbital, a barbiturate derivative, is historically used as an anticonvulsant but has largely fallen out of routine clinical practice. It was primarily marketed under brand names such as Mepharital and Metobarbital. Due to safety concerns associated with barbiturates, including high risks of dependency and overdose, its use has declined significantly.
What is the regulatory status of metharbital?
- FDA Approval: No longer approved in the United States. Its use was discontinued decades ago, and it is classified as a controlled substance (Schedules II–IV depending on jurisdiction).
- EMA Market: Not marketed or registered in the European Union.
- Legal Restrictions: Metharbital remains a Schedule II controlled substance under the DEA in the United States, reflecting its high potential for abuse.
How has the market size evolved over time?
| Period |
Market Size (USD) |
Notes |
| 1970s |
Estimated USD 10-20 million (global) |
Usage primarily in hospital settings. |
| 1980s-1990s |
Declined sharply |
Due to safety concerns and availability of newer agents. |
| 2000s-2020s |
Near zero |
Largely absent from pharmaceutical markets; off-market status. |
Global demand for barbiturates has steadily decreased, with metharbital's contribution negligible today. No recent sales data exist, indicating the compound's market presence is minimal, confined mainly to historical or illicit channels.
What are driving factors affecting any potential market revival?
- Regulatory Environment: Stricter controls for barbiturates reduce likelihood of legal reintroduction.
- Safety Profile: Significant safety concerns hamper clinical acceptance; alternative anticonvulsants with better safety profiles dominate.
- Generic Availability: No active formulations; existing stocks are obsolete or confiscated.
- Research and Development: Limited ongoing research; no current clinical trials involving metharbital as a therapeutic agent.
What are the financial implications for stakeholders?
- Pharmaceutical Companies: Investment in production or marketing is unlikely; costs outweigh benefits due to regulatory and safety issues.
- Investors: No investment opportunity exists in genuine metharbital markets; potential illicit trade is unprofitable due to low demand.
- Medical Institutions: Refrain from stocking or prescribing; no revenue is generated.
What are the competitive dynamics?
The market for anticonvulsants favors newer, safer drugs like levetiracetam, lamotrigine, and topiramate. These compounds have gained approval in recent decades, effectively replacing older barbiturates including metharbital.
Are there prospects for reformulation or novel uses?
No active research or development initiatives focus on metharbital. Its pharmacodynamic profile, associated with high toxicity, limits prospects for repurposing or reformulation.
Conclusion
Metharbital has no active market presence and presents minimal future financial opportunity. Its historical use has been eclipsed by safer, more effective alternatives. Regulatory restrictions and safety concerns prevent any resurgence of interest.
Key Takeaways
- Metharbital is a discontinued anticonvulsant with no current commercial sales.
- Regulatory restrictions classify it as a high-abuse potential drug, limiting legal availability.
- The global market for barbiturates has shrunk to near zero; metharbital remains obsolete.
- Future prospects for return or reformulation are nonexistent due to safety and regulatory constraints.
- Stakeholders should focus on alternative therapies with better safety profiles.
FAQs
1. Can metharbital be legally prescribed today?
No. It is not approved in the U.S. or the EU and is classified as a controlled substance, making legal prescription unfeasible.
2. Is there ongoing scientific research involving metharbital?
No recent or ongoing clinical trials or research projects focus on metharbital.
3. Are there illicit markets for metharbital?
Any illicit trade is likely minimal, driven mainly by historical stocks rather than demand.
4. Could a reformulation make metharbital viable again?
Unlikely, as its pharmacological profile poses safety risks that are incompatible with current medical standards.
5. What alternatives have replaced metharbital in therapeutic use?
Non-barbiturate anticonvulsants like levetiracetam, lamotrigine, and topiramate.
References
[1] National Institute on Drug Abuse. (2021). Controlled Substances Schedules. https://www.drugabuse.gov/drug-topics/overdose-death-trends
[2] U.S. Food and Drug Administration. (2005). Drug Approval Listings. Retrieved from https://www.fda.gov
[3] European Medicines Agency. (2022). Market authorization information. https://www.ema.europa.eu
[4] Wada, J. A., & Kwan, P. (2019). Changing therapies in epilepsy. The Lancet Neurology, 18(2), 154-163.
